Dimitris Voliotis - Feb 10, 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
SVP, Clinical Development
Signature
/s/ Melissa B. Epperly, Attorney-in-Fact for Dimitris Voliotis
Stock symbol
ZNTL
Transactions as of
Feb 10, 2022
Transactions value $
-$30,188
Form type
4
Date filed
2/14/2022, 08:10 PM
Previous filing
Jan 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Award $0 +10.3K +165.26% $0.00 16.6K Feb 10, 2022 Direct F1
transaction ZNTL Common Stock Sale -$26.8K -534 -3.22% $50.16 16K Feb 14, 2022 Direct F2, F3
transaction ZNTL Common Stock Sale -$3.4K -67 -0.42% $50.75 16K Feb 14, 2022 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +24.2K $0.00 24.2K Feb 10, 2022 Common Stock 24.2K $52.61 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
F2 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.